



DEPARTMENT OF HEALTH & HUMAN SERVICES

HFD-310 (Assignment file)  
Public Health Service

Food and Drug Administration  
Rockville MD 20857

WARNING LETTER

MAR 3 1998

Longevity Products, LTD  
P.O. Box 561, Suite 6/588  
28 City Mill Lane  
Gibraltar, Europe

Ref: 98-HFD-310-02

Dear Chief Executive Officer:

The United States Food and Drug Administration (FDA) has been informed that your firm is soliciting the citizens of the United States to purchase various unapproved prescription drugs. These drugs may not be legally marketed in this country. Therefore, your activities are in serious violation of the Federal Food, Drug, and Cosmetic Act.

The FDA considers these drugs to be in violation of Title 21 United States Code (U.S.C.) 355(a) because they are new drugs without approved new drug applications. In addition, these prescription drugs appear to be misbranded in that they lack adequate directions for use [Title 21 U.S.C. 352(f)(1)].

The FDA does not permit the personal importation of drugs when: 1) they are promoted to persons residing in the United States; and 2) they pose an unreasonable risk to public health.

We are taking steps to warn our citizens that these drugs are not approved for marketing in this country and may not be legally imported. By this letter, we are also advising the regulatory drug officials in the countries from which you operate of these violations.

We have advised other federal officials through an Import alert that all shipments found entering the United States as a result of such activities shall be automatically detained and refused entry.

The violations listed above are not intended to be all inclusive.

Please notify this office in writing of the specific steps you have taken to correct these serious violations within 15 working days of the receipt of this letter.

Page 2 - Longevity Products, LTD.

Your reply should be addressed to the following:

Donald L. Leggett  
United States Food and Drug Administration  
7520 Standish Place  
Rockville, Maryland USA 20855

Sincerely,



Bradford W. Williams

Director

Division of Labeling and Nonprescription Drugs

Office of Compliance

Center for Drug Evaluation and Research

Enclosure:

Import Alert/Press Release